ArticleBlood cancer journal2020
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma.
Article in Blood cancer journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 8 syntheses or guidelines pooled it, 250 citations in OpenAlex.
- Central nervous system infections caused by carbapenem-resistant klebsiella pneumoniae after CAR T-cell therapy in a patient with preexisting colonization: a case report and literature review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies.Transplantation and cellular therapy · 2024Guideline
- Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.Annals of medicine · 2022Pooled it
- Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.Transplantation and cellular therapy · 2022Guideline
- Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.Bone marrow transplantation · 2022Pooled it
- Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.Frontiers in immunology · 2021Pooled it
- The Association Between Glucocorticoid Administration and the Risk of Impaired Efficacy of Axicabtagene Ciloleucel Treatment: A Systematic Review.Frontiers in immunology · 2021Pooled it
- Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation.The Journal of clinical investigation · 2020Trial
- Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis.Blood advances · 2026Article
- CAR T cells against the B cell receptor to precisely eliminate pathogenic B cells.Molecular therapy. Oncology · 2026Article
- Early infection post targeted chimeric antigen receptor T-cell therapy in patients with hematologic malignancies: a real-world, single-center, large-scale study.Bone marrow transplantation · 2026Article
- Predictive Models for Toxicities after CAR T-cell Therapy: Challenges and Opportunities.Blood cancer discovery · 2026Review
- B Cell Aplasia Following CAR T Cell Therapy: Incidence, Kinetics, Prognostic Implications, and Clinical Management.Cancers · 2026Review
- Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance Study.Children (Basel, Switzerland) · 2026Article
- ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.Haematologica · 2026Article
- Late Complications After European Medicines Agency-Approved Chimeric Antigen Receptor T-Cell Therapy in Hematological Malignancies: A Scoping Review.Current oncology (Toronto, Ont.) · 2026Article
- Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.Open forum infectious diseases · 2026Article
- Article
- Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.Transplantation and cellular therapy · 2026Article
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 3 countries.
Funding
Abstract
CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), B cell aplasia and hypogammaglobulinemia are common toxicities predisposing these patients to infections. We analyzed 60 patients with DLBCL treated with FDA-approved CD19 CAR T cells and report the incidence, risk factors, and management of infections during the first year after treatment. A total of 101 infectious events were observed, including 25 mild, 51 moderate, 23 severe, 1 life-threatening, and 1 fatal infection. Bacteria were the most common causative pathogens. The cumulative incidence of overall, bacterial, severe bacterial, viral, and fungal infection at 1 year were 63.3%, 57.2%, 29.6%, 44.7%, and 4%, respectively. In multivariate analyses, the use of systemic corticosteroids for the management of CRS or ICANS was associated with an increased risk of infections and prolonged admission. Impaired performance status and history of infections within 30 days before CAR T cell therapy was a risk factor for severe bacterial infection. In conclusion, infections were common within the first 60 days after CAR T cell therapy, however, they were not associated with an increased risk of death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.